Esomeprazole + Placebo

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Chronic Posterior Laryngitis (CPL)

Conditions

Chronic Posterior Laryngitis (CPL)

Trial Timeline

Feb 1, 2002 → Mar 1, 2003

About Esomeprazole + Placebo

Esomeprazole + Placebo is a approved stage product being developed by AstraZeneca for Chronic Posterior Laryngitis (CPL). The current trial status is completed. This product is registered under clinical trial identifier NCT00628667. Target conditions include Chronic Posterior Laryngitis (CPL).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Posterior Laryngitis (CPL) were approved

Approved (20) Terminated (3) Active (0)
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
alefaceptAstellas PharmaApproved
AlefaceptAstellas PharmaApproved
lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT01069939Phase 3Completed
NCT00660660ApprovedCompleted
NCT00542789Phase 3Completed
NCT00287339ApprovedCompleted
NCT00745849Pre-clinicalCompleted
NCT00628953Phase 2Completed
NCT00628667ApprovedCompleted

Competing Products

20 competing products in Chronic Posterior Laryngitis (CPL)

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25